Citation: 4A_11/2022 E. B

Am 28. Juni 2019 reichte die Klägerin beim Bundespatentgericht Klage ein mit den folgenden Rechtsbegehren (die Unterschiede in den zunehmend enger gefassten Rechtsbegehren 1-3 sowie 4-7 sind jeweils hervorgehoben) : "1. Defendant shall be prohibited, under threat of an administrative fine of CHF 1,000 per day of non-compliance pursuant to Article 343 (1) (c) CCP, but of at least CHF 5,000 pursuant to Article 343 (1) (b) CCP, as well as punishment of its organs pursuant to Article 292 CC in the event of non-compliance, from manufacturing, importing into Switzerland, exporting from Switzerland, offering in Switzerland, selling in Switzerland, putting in circulation otherwise in Switzerland, storing in Switzerland the following product, be it alone or as part of a kit: a modified nucleotide molecule comprising a purine or pyrimidine base and a ribose or deoxyribose sugar moiety having a removable 3'-OH blocking group covalently attached thereto such that the 3' carbon atom has attached a group of the structure -O-Z wherein Z comprises an azido group and is (-CR'2 -N3) and wherein each R' is independently a hydrogen atom, an alkyl, substituted alkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, acyl, cyano, alkoxy, aryloxy, heteroaryloxy or amido group, or a detectable label attached through a linking group, or R'2 represents an alkylidene group of formula =C (R"') 2 wherein each R"' may be the same or different and is selected from the group comprising hydrogen and halogen atoms and alkyl groups;